April 2014 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012 and 2013/14 Invitation to Tender, dated 07 November 2013.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
CORRECTION to MARCH 2014 tender notification: in bold and strikethrough
Tenders awarded to listed pharmaceuticals where only the current brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current pack price | New pack price | Hospital Supply Brand (Supplier) |
DV Limit |
Date of price change | Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
| Acetazolamide | Tab 250 mg; 100 tablets, bottle |
$17.03 | $17.03 | Diamox (Aspen) |
1% | 1 July 2014 | 1 September 2014 |
2012/13 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2016
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current subsidy and (price) | New subsidy and price | Sole supply brand (Supplier) |
Date of listing/subsidy change for tender winning brand | Date of reference pricing of other listed brands | Sole Subsidised Supply date (and delisting of other listed brands) | Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
| Fusidic acid | crm 2%; 15 g OP, tube |
$3.25 | $2.52 | DP Fusidic Acid Cream (Douglas) |
1 November 2014 | 1 January 2015 | 1 April 2015 | Foban (AFT) |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current pack price | New pack price |
Hospital Supply Brand (Supplier) |
DV Limit |
Date of listing/price change for tender winning brand | Hospital Supply Status date (and delisting of other listed brands) | Brand (Supplier) to be delisted |
|---|---|---|---|---|---|---|---|---|
| Fusidic acid | crm 2%; 15 g, tube |
$3.25 | $2.52 | DP Fusidic Acid Cream (Douglas) |
1% | 1 November 2014 | 1 January 2015 | Foban (AFT) |
2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current subsidy and (price) | New subsidy and price | Sole supply brand (Supplier) |
Date of listing/subsidy change for tender winning brand | Date of reference pricing of other listed brands | Sole Subsidised Supply date (and delisting of other listed brands) | Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
| Acitretin | cap 10 mg; 60 capsules, blister pack |
$38.66 | $17.86 | Novatretin (Douglas) |
1 September 2014 | 1 November 2014 | 1 February 2015 | Neotigason (Actavis) |
| Acitretin | cap 25 mg; 60 capsules, blister pack |
$83.11 | $41.36 | Novatretin (Douglas) |
1 September 2014 | 1 November 2014 | 1 February 2015 | Neotigason (Actavis) |
| Amoxicillin with clavulanic acid | tab 500 mg with clavulanic acid 125 mg; 20 tablets, blister pack |
$12.55 per 100 tablets | $1.95 per 20 tablets | Augmentin (GSK) |
1 September 2014 | 1 November 2014 | 1 February 2015 | Curam Duo (Sandoz) |
| Ciprofloxacin | tab 500 mg; 28 tablets, blister pack |
$3.00 per 28 tablets | $2.00 per 28 tablets | Cipflox (Mylan) |
1 July 2014 | 1 September 2014 | 1 December 2014 | Cipflox -100 tablet packsize (Mylan) |
| Ciprofloxacin | tab 750 mg; 28 tablets, blister pack |
$5.15 | $3.75 | Cipflox (Mylan) |
1 July 2014 | 1 September 2014 | 1 December 2014 | Ciprofloxacin Rex (Rex Medical) |
| Cyproterone acetate with ethinyloestradiol 1 | tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets; 168 tablets, blister pack (6 x 21 active tablets and 6 x 7 placebo tablets, blister pack) |
$3.89 per 84 tablets | $5.36 per 168 tablets | Ginet (Rex Medical) |
1 October 2014 | 1 December 2014 | 1 March 2015 | Ginet 84 tablet packsize (Rex Medical) |
| Gliclazide 2 | tab 80 mg; 500 tablets, bottle |
$17.60 | $11.50 | Glizide (Mylan) |
1 September 2014 | 1 November 2014 | 1 February 2015 | Apo-Gliclazide (Apotex) |
| Ibuprofen 3 | tab 200 mg; 1,000 tablets, blister pack |
$12.75 | $9.45 | Ibugesic (Rex Medical) |
1 December 2014 | 1 February 2015 | 1 May 2015 | Arrowcare (Actavis) |
| Lamivudine | tab 100 mg; 28 tablets, blister pack |
$32.50 | $6.00 | Zeffix (GSK) |
1 September 2014 | 1 November 2014 | 1 February 2015 | Zetlam (Mylan) |
| Nifedipine | tab long-acting 30 mg; 30 tablets, blister pack |
$8.56 | $3.75 | Adefin XL (Mylan) |
1 July 2014 | 1 September 2014 | 1 December 2014 | Arrow-Nifedipine XR (Arrow) Adalat Oros (Bayer) |
| Nifedipine | tab long-acting 60 mg; 30 tablets, blister pack |
$12.28 | $5.75 | Adefin XL (Mylan) |
1 July 2014 | 1 September 2014 | 1 December 2014 | Arrow-Nifedipine XR (Arrow) Adalat Oros (Bayer) |
| Pamidronate disodium | inj 3 mg per ml, 10 ml vial; 1 vial |
$16.00 | $6.80 | Pamisol (Hospira) |
1 July 2014 | 1 September 2014 | 1 December 2014 | Pamidronate BNM (Boucher) |
| Pamidronate disodium | inj 6 mg per ml, 10 ml vial; 1 vial |
$32.00 | $13.20 | Pamisol (Hospira) |
1 July 2014 | 1 September 2014 | 1 December 2014 | Pamidronate BNM (Boucher) |
| Pamidronate disodium | inj 9 mg per ml, 10 ml vial; 1 vial |
$48.00 | $19.20 | Pamisol (Hospira) |
1 July 2014 | 1 September 2014 | 1 December 2014 | Pamidronate BNM (Boucher) |
| Paracetamol | oral liq 120 mg per 5 ml; 1,000 ml, bottle |
$2.21 per 500 ml | $4.15 per 1,000 ml | Paracare (API) |
1 August 2014 | 1 October 2014 | 1 January 2015 | Ethics Paracetamol (Multichem) |
| Paracetamol | tab 500 mg; 1,000 tablets, blister pack |
$9.38 | $8.47 | Pharmacare (API) |
1 September 2014 | 1 November 2014 | 1 February 2015 | Parafast (Actavis) |
| Potassium iodate | tab 253 mcg (150 mcg elemental iodine); 90 tablets, bottle |
$6.53 | $3.65 | NeuroTabs (AFT) |
1 October 2014 | 1 December 2014 | 1 March 2015 | NeuroKare (Alaron) |
| Ranitidine | tab 150 mg; 500 tablets, blister pack |
$6.79 per 250 tablets | $10.30 per 500 tablets | Ranitidine Relief (Mylan) |
1 September 2014 | 1 November 2014 | 1 February 2015 | Arrow-Ranitidine (Actavis) |
| Ranitidine | tab 300 mg; 500 tablets, blister pack |
$9.34 per 250 tablets | $14.73 per 500 tablets | Ranitidine Relief (Mylan) |
1 September 2014 | 1 November 2014 | 1 February 2015 | Arrow-Ranitidine (Actavis) |
|
||||||||
Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy and (price) | New subsidy and price | Sole supply brand (Supplier) | Date of subsidy change | Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
| Ciprofloxacin | tab 250 mg; 28 tablets, blister pack |
$2.20 | $1.75 | Cipflox (Mylan) |
1 July 2014 | 1 October 2014 |
| Exemestane | tab 25 mg; 30 tablets, blister pack |
$22.57 | $14.50 | Aromasin (Pfizer) |
1 July 2014 | 1 October 2014 |
| Lamivudine | oral liq 5 mg per ml; 240 ml, bottle |
$90.00 | $270.00 | Zeffix (GSK) |
1 September 2014 | 1 December 2014 |
| Paracetamol | oral liq 250 mg per 5 ml; 1,000 ml, bottle |
$6.70 | $4.35 | Paracare Double Strength (API) |
1 July 2014 | 1 October 2014 |
| Pravastatin | tab 20 mg; 30 tablets, blister pack |
$5.44 | $3.45 | Cholvastin (Douglas) |
1 August 2014 | 1 November 2014 |
| Pravastatin | tab 40 mg; 30 tablets, blister pack |
$9.28 | $6.36 | Cholvastin (Douglas) |
1 August 2014 | 1 November 2014 |
| Rizatriptan | tab orodispersible 10 mg; 30 tablets, blister pack |
$18.00 | $8.10 | Rizamelt (Mylan) |
1 July 2014 | 1 October 2014 |
| Zidovudine [AZT] with lamivudine | tab 300 mg with lamivudine 150 mg; 60 tablets, bottle |
$63.50 | $44.00 | Alphapharm (Mylan) |
1 July 2014 | 1 October 2014 |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current pack price | New pack price |
Hospital Supply Brand (Supplier) |
DV Limit |
Date of listing/price change for tender winning brand | Hospital Supply Status date (and delisting of other listed brands) | Brand (Supplier) to be delisted |
|---|---|---|---|---|---|---|---|---|
| Acitretin | cap 10 mg; 60 capsules, blister pack |
$38.66 | $17.86 | Novatretin (Douglas) |
1% | 1 September 2014 | 1 November 2014 | Neotigason (Actavis) |
| Acitretin | cap 25 mg; 60 capsules, blister pack |
$83.11 | $41.36 | Novatretin (Douglas) |
1% | 1 September 2014 | 1 November 2014 | Neotigason (Actavis) |
| Amoxicillin with clavulanic acid | tab 500 mg with clavulanic acid 125 mg; 20 tablets, blister pack |
$12.55 per 100 tablets | $1.95 per 20 tablets | Augmentin (GSK) |
1% | 1 September 2014 | 1 November 2014 | Curam Duo (Sandoz) |
| Ceftazidime | inj 1 g vial; 1 vial |
$3.25 | $1.55 | Fortum (GSK) |
1% | 1 August 2014 | 1 October 2014 | DBL Ceftazidime (Hospira) |
| Ceftazidime | inj 2 g vial; 1 vial |
$6.49 | $3.34 | Fortum (GSK) |
1% | 1 August 2014 | 1 October 2014 | DBL Ceftazidime (Hospira) |
| Cefuroxime | inj 750 mg vial; 5 vials |
$6.96 | $3.70 | Zinacef (GSK) |
1% | 1 September 2014 | 1 November 2014 | m-Cefuroxime (Multichem) |
| Cefuroxime | inj 1.5g vial; 1 vial |
$2.65 | $1.30 | Zinacef (GSK) |
1% | 1 September 2014 | 1 November 2014 | Mylan (Mylan) |
| Gliclazide | tab 80 mg; 500 tablets, bottle |
$17.60 | $11.50 | Glizide (Mylan) |
1% | 1 September 2014 | 1 November 2014 | Apo-Gliclazide (Apotex) |
| Lamivudine | tab 100 mg; 28 tablets, blister pack |
$32.50 | $6.00 | Zeffix (GSK) |
1% | 1 September 2014 | 1 November 2014 | Zetlam (Mylan) |
| Nifedipine | tab long-acting 30 mg; 30 tablets, blister pack |
$8.56 | $3.75 | Adefin XL (Mylan) |
1% | 1 July 2014 | 1 September 2014 | Arrow-Nifedipine XR (Arrow) |
| Nifedipine | tab long-acting 60 mg; 30 tablets, blister pack |
$12.28 | $5.75 | Adefin XL (Mylan) |
1% | 1 July 2014 | 1 September 2014 | Arrow-Nifedipine XR (Arrow) |
| Pamidronate disodium | inj 3 mg per ml, 10 ml vial; 1 vial |
$16.00 | $6.80 | Pamisol (Hospira) |
1% | 1 July 2014 | 1 September 2014 | Pamidronate BNM (Boucher) |
| Pamidronate disodium | inj 6 mg per ml, 10 ml vial; 1 vial |
$32.00 | $13.20 | Pamisol (Hospira) |
1% | 1 July 2014 | 1 September 2014 | Pamidronate BNM (Boucher) |
| Pamidronate disodium | inj 9 mg per ml, 10 ml vial; 1 vial |
$48.00 | $19.20 | Pamisol (Hospira) |
1% | 1 July 2014 | 1 September 2014 | Pamidronate BNM (Boucher) |
| Paracetamol | inj 10 mg per ml, 50 ml vial; 12 vials |
$22.50 | $12.90 | Perfalgan (BMS) |
1% | 1 July 2014 | 1 September 2014 | Paracetamol-AFT (AFT) |
| Paracetamol | inj 10 mg per ml, 100 ml vial; 12 vials |
$22.50 | $12.90 | Perfalgan (BMS) |
1% | 1 July 2014 | 1 September 2014 | Paracetamol-AFT (AFT) |
| Paracetamol | oral liq 120 mg per 5 ml; 1,000 ml, bottle |
$2.21 per 500 ml | $4.15- per 1,000 ml | Paracare (API) |
20% | 1 August 2014 | 1 October 2014 | Ethics Paracetamol (Multichem) |
| Ranitidine | tab 150 mg; 500 tablets, blister pack |
$6.79 per 250 tablets | $10.30 per 500 tablets | Ranitidine Relief (Mylan) |
1% | 1 September 2014 | 1 November 2014 | Arrow-Ranitidine (Actavis) |
| Ranitidine | tab 300 mg; 500 tablets, blister pack |
$9.34 per 250 tablets | $14.73 per 500 tablets | Ranitidine Relief (Mylan) |
1% | 1 September 2014 | 1 November 2014 | Arrow-Ranitidine (Actavis) |
| Remifentanil hydrochloride | inj 1 mg vial; 5 vials |
$27.95 | $10.00 | Ultiva (GSK) |
1% | 1 September 2014 | 1 November 2014 | Remifentanil-AFT (AFT) |
| Remifentanil hydrochloride | inj 2 mg vial; 5 vials |
$41.80 | $18.00 | Ultiva (GSK) |
1% | 1 September 2014 | 1 November 2014 | Remifentanil-AFT (AFT) |
Tenders awarded to listed pharmaceuticals where only the current brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current pack price | New pack price | Hospital Supply Brand (Supplier) |
DV Limit |
Date of price change | Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
| Ceftazidime | inj 500 mg vial; 1 vial |
$2.37 | $5.30 | Fortum (GSK) |
1% | 1 August 2014 | 1 October 2014 |
| Ciprofloxacin | tab 250 mg; 28 tablets, blister pack |
$2.20 | $1.75 | Cipflox (Mylan) |
1% | 1 July 2014 | 1 September 2014 |
| Ciprofloxacin | tab 500 mg; 28 tablets, blister pack |
$3.00 | $2.00 | Cipflox (Mylan) |
1% | 1 July 2014 | 1 September 2014 |
| Ciprofloxacin | tab 750 mg; 28 tablets, blister pack |
$5.15 | $3.75 | Cipflox (Mylan) |
1% | 1 July 2014 | 1 September 2014 |
| Exemestane | tab 25 mg; 30 tablets, blister pack |
$22.57 | $14.50 | Aromasin (Pfizer) |
1% | 1 July 2014 | 1 September 2014 |
| Lamivudine | oral liq 5 mg per ml; 240 ml, bottle |
$90.00 | $270.00 | Zeffix (GSK) |
1% | 1 September 2014 | 1 November 2014 |
| Paracetamol | oral liq 250 mg per 5 ml; 1,000 ml, bottle |
$6.70 | $4.35 | Paracare Double Strength (API) |
20% | 1 July 2014 | 1 September 2014 |
| Pravastatin | tab 20 mg; 30 tablets, blister pack |
$5.44 | $3.45 | Cholvastin (Douglas) |
1% | 1 August 2014 | 1 October 2014 |
| Pravastatin | tab 40 mg; 30 tablets, blister pack |
$9.28 | $6.36 | Cholvastin (Douglas) |
1% | 1 August 2014 | 1 October 2014 |
| Rizatriptan | tab orodispersible 10 mg; 30 tablets, blister pack |
$18.00 | $8.10 | Rizamelt (Mylan |
1% | 1 July 2014 | 1 September 2014 |
| Zidovudine [AZT] with lamivudine | tab 300 mg with lamivudine 150 mg; 60 tablets, bottle |
$63.50 | $44.00 | Alphapharm (Mylan) |
1% | 1 July 2014 | 1 September 2014 |
Tenders awarded to pharmaceuticals where no brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Pack price | Hospital Supply Brand (Supplier) |
DV Limit |
Listing date | Hospital Supply Status date |
|---|---|---|---|---|---|---|
| Cyproterone acetate with ethinyloestradiol | tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets; 168 tablets, blister pack (6 x 21 active tablets and 6 x 7 placebo tablets, blister pack) |
$5.36 | Ginet (Rex Medical) |
1% | 1 October 2014 | 1 December 2014 |
| Potassium iodate | tab 253 mcg (150 mcg elemental iodine); 90 tablets, bottle |
$3.65 | NeuroTabs (AFT) |
1% | 1 October 2014 | 1 December 2014 |
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2013/14 Invitation to Tender, dated 07 November 2013:
2013/14 Invitation to Tender
| Chemical Name | Line Item | Chemical Name | Line Item |
|---|---|---|---|
| Adapalene | Crm 0.1% | Adapalene | Gel 0.1% |
| Ciprofloxacin | Oral liq 100mg per ml | Ciprofloxacin | Oral liq 50mg per ml |
| Glyceryl trinitrate | Tab 500 mcg - 600 mcg | Nifedipine | Cap 5 mg |
| Pamidronate disodium * | Inj 3 mg per ml, 5 ml * | Pancreatic enzyme | Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease |
| Pancreatic enzyme | Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease | Pancreatic enzyme | Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease |
| Pancreatic enzyme | Powder | Verapamil hydrochloride | Tab long-acting 120 mg |
| Verapamil hydrochloride | Tab long-acting 240 mg | ||
| Note: pamidronate disodium- inj 3 mg per ml, 5 ml will be delisted from 1 December 2014 in Section B of the Pharmaceutical Schedule and 1 September 2014 from Part II of Section H of the Pharmaceutical Schedule. | |||
PHARMAC has resolved not to award tenders for Hospital Supply Status for the following products listed in the 2013/14 Invitation to Tender, dated 07 November 2013:
| Chemical Name | Line Item | Chemical Name | Line Item |
|---|---|---|---|
| Paracetamol | Tab 500 mg | Ibuprofen | Tab 200 mg |
For products included in the 2011/12 Invitation to Tender, 2012/13 or the 2013/14 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.